Privacy Analytics, Inc. announced the availability of a new solution designed to enable pharmaceutical companies to share clinical trials data while protecting the privacy of the individual patients.
Privacy Analytics, Inc. announced the availability of a new solution designed to enable pharmaceutical companies to share clinical trials data while protecting the privacy of the individual patients. Privacy Analytics' Open Clinical Trials Data Review, which runs on the company's automated risk-assessment, data request, PARAT software, compares existing industry anonymization approaches and finds privacy gaps.
The new offering accelerates the ability of pharmaceutical companies to meet increasing requests for individual-level participant data and clinical study reports by academicinstitutions, patients and other third-parties.
For privacy, regulatory and medical affairs executives, Privacy Analytics now provides:
Read the full release here.
Truqap Combination Shines in Phase III Trial for Prostate Cancer
November 26th 2024Data from the CAPItello-281 trial show Truqap alongside abiraterone and androgen deprivation therapy achieved a statistically significant and clinically meaningful improvement in radiographic progression-free survival.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.